Zeltiq Aesthetics Inc. (ZLTQ) Insider Mark J. Foley Sells 10,000 Shares of Stock
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) insider Mark J. Foley sold 10,000 shares of the company’s stock in a transaction on Thursday, October 13th. The stock was sold at an average price of $40.55, for a total transaction of $405,500.00. Following the completion of the sale, the insider now owns 281,941 shares of the company’s stock, valued at $11,432,707.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) opened at 39.47 on Monday. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of 59.35 and a beta of 0.79. Zeltiq Aesthetics Inc. has a 12 month low of $18.41 and a 12 month high of $41.48. The stock’s 50 day moving average is $39.20 and its 200-day moving average is $32.39.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.07. Zeltiq Aesthetics had a negative return on equity of 9.90% and a net margin of 9.54%. The company had revenue of $89.50 million for the quarter, compared to analyst estimates of $79.68 million. During the same quarter in the previous year, the business earned $0.03 earnings per share. The company’s revenue was up 38.9% on a year-over-year basis. On average, analysts anticipate that Zeltiq Aesthetics Inc. will post ($0.13) earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of the company. FMR LLC raised its stake in shares of Zeltiq Aesthetics by 45.2% in the second quarter. FMR LLC now owns 4,277,811 shares of the company’s stock valued at $116,913,000 after buying an additional 1,332,129 shares during the last quarter. BlackRock Fund Advisors raised its stake in shares of Zeltiq Aesthetics by 9.5% in the second quarter. BlackRock Fund Advisors now owns 2,297,982 shares of the company’s stock valued at $62,804,000 after buying an additional 199,946 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Zeltiq Aesthetics by 30.7% in the second quarter. Point72 Asset Management L.P. now owns 2,219,762 shares of the company’s stock valued at $60,666,000 after buying an additional 521,462 shares during the last quarter. Aisling Capital LLC raised its stake in shares of Zeltiq Aesthetics by 0.3% in the second quarter. Aisling Capital LLC now owns 2,109,727 shares of the company’s stock valued at $57,659,000 after buying an additional 6,199 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Zeltiq Aesthetics by 4.1% in the second quarter. Vanguard Group Inc. now owns 1,569,585 shares of the company’s stock valued at $42,897,000 after buying an additional 61,700 shares during the last quarter.
ZLTQ has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a report on Saturday, July 23rd. Leerink Swann reiterated a “buy” rating on shares of Zeltiq Aesthetics in a report on Thursday, June 30th. Brean Capital reiterated a “buy” rating and issued a $35.00 price objective on shares of Zeltiq Aesthetics in a report on Tuesday, June 21st. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $35.00 price objective (up from $27.00) on shares of Zeltiq Aesthetics in a report on Tuesday, August 9th. Finally, Stifel Nicolaus upped their price objective on shares of Zeltiq Aesthetics from $38.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, September 21st. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $39.89.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.